

Najmeh Moradi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9178969/publications.pdf>

Version: 2024-02-01

27
papers

232
citations

1162367

8
h-index

1058022

14
g-index

33
all docs

33
docs citations

33
times ranked

301
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review. <i>Value in Health Regional Issues</i> , 2022, 30, 31-38.	0.5	3
2	Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. <i>Archives of Iranian Medicine</i> , 2021, 24, 139-143.	0.2	21
3	Willingness to pay for and acceptance of cervical cancer prevention methods: A systematic review and meta-analysis. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 81.	0.9	2
4	Public Views on Priority Groups for COVID-19 Vaccination: A Survey from Iran. <i>Shiraz E Medical Journal</i> , 2021, 22, .	0.1	2
5	Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 35.	0.6	8
6	The effect of risk communication on preventive and protective Behaviours during the COVID-19 outbreak: mediating role of risk perception. <i>BMC Public Health</i> , 2021, 21, 54.	1.2	68
7	Barriers and Drivers of Public Preventive Behavioral Responses to COVID-19 Outbreak: Evidence from Iran. <i>Health Scope</i> , 2021, 10, .	0.4	4
8	Private Demand for Covid-19 Vaccine: A Contingent Assessment from a Low-and Middle-income Country.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 223-234.	0.3	4
9	Men's willingness to pay for prostate cancer screening: a systematic review. <i>Systematic Reviews</i> , 2020, 9, 290.	2.5	9
10	An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 47.	0.6	4
11	Evaluating the preventive and curative effects of <i>Toxocara canis</i> larva in Freund's complete adjuvant-induced arthritis. <i>Parasite Immunology</i> , 2020, 42, e12760.	0.7	3
12	Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1710.	1.2	6
13	An application of analytic network process model in supporting decision making to address pharmaceutical shortage. <i>BMC Health Services Research</i> , 2020, 20, 626.	0.9	6
14	Affordability of Medication Therapy in Diabetic Patients: A Scenario-Based Assessment in Iran's Health System Context. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	3
15	Managing Pharmaceutical Expenditures: Estimating the Effect of Internal Reference Pricing for Three Pharmacological Categories. <i>Avicenna Journal of Pharmaceutical Research</i> , 2020, 1, 76-81.	0.2	0
16	COVID-19: The Challenge of Disadvantaged Groups and their Access to Care. <i>Archives of Iranian Medicine</i> , 2020, 23, 647-648.	0.2	0
17	High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. <i>Archives of Virology</i> , 2019, 164, 2493-2504.	0.9	15
18	The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. <i>PharmacoEconomics - Open</i> , 2019, 3, 311-319.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration. DARU, Journal of Pharmaceutical Sciences, 2019, 27, 169-177.	0.9	12
20	Willingness to pay for one quality-adjusted life year in Iran. Cost Effectiveness and Resource Allocation, 2019, 17, 4.	0.6	13
21	Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. Archives of Virology, 2019, 164, 349-357.	0.9	7
22	Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran. Applied Health Economics and Health Policy, 2018, 16, 837-846.	1.0	13
23	Health State Utilities for Patient's Current Health from Bipolar Type I Disorder. Journal of Mental Health Policy and Economics, 2018, 21, 3-10.	0.6	2
24	How to Maintain Pharmaceutical Access in Crisis: The Iran FDA Experience. Value in Health, 2017, 20, A665-A666.	0.1	0
25	Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP). Iranian Journal of Pharmaceutical Research, 2017, 16, 823-833.	0.3	9
26	Willingness to Pay for Complementary Health Care Insurance in Iran. Iranian Journal of Public Health, 2017, 46, 1247-1255.	0.3	3
27	Willingness to Pay for One Quality Adjusted Life Years In Patients With Diabetes. Value in Health, 2015, 18, A616-A617.	0.1	6